New phase III data further support the safety and efficacy profile of Boehringer Ingelheim’s investigational drug linagliptin

Linagliptin continues to differentiate itself as potential future option for patients with type 2 diabetes, regardless of stage of the condition or kidney function - For non-US healthcare media

Ingelheim, Germany, 22 September 2010 – New data from the linagliptin late stage clinical trial programme were presented this week at the 46 th Annual Meeting of the European Association for the Study of Diabetes (EASD). The studies included two phase III trials: one investigating linagliptin monotherapy in type 2 diabetes patients for whom metformin therapy is inappropriate, 1 and the other studying linagliptin as add-on therapy to a sulphonylurea in patients with inadequately controlled type 2 diabetes. 2 In addition, a pharmacokinetic study was presented at the congress which investigated linagliptin in a special patient population with different degrees of renal impairment. 3